MARKET

QTTB

QTTB

Q32 BIO INC
NASDAQ
8.77
-0.45
-4.88%
Closed 19:46 09/25 EDT
OPEN
9.20
PREV CLOSE
9.22
HIGH
9.20
LOW
8.74
VOLUME
515.63K
TURNOVER
0
52 WEEK HIGH
23.57
52 WEEK LOW
1.780
MARKET CAP
261.08M
P/E (TTM)
2.933
1D
5D
1M
3M
1Y
5Y
1D
Q32 Bio initiated with a Buy at Jefferies
TipRanks · 5h ago
Weekly Report: what happened at QTTB last week (0921-0925)?
Weekly Report · 6h ago
Q32 Bio: Durable Hair Regrowth Remains The Goal
Seeking Alpha · 2d ago
Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing
Seeking Alpha · 3d ago
AM Markets Need to Know: F-35 parts end up in Chinese custody, Google nears Gemini 4 launch, and more
Seeking Alpha · 4d ago
Gene editing stocks fall after report on Anthropic’s CRISPR-like discovery
Seeking Alpha · 4d ago
These four healthcare stocks have held Strong Buy ratings for 60+ days
Seeking Alpha · 5d ago
Q32 Bio Presents Additional 36-Week Data From Its Part B Of SIGNAL-AA Phase 2a Clinical Study Of Bempikibart At European Academy Of Dermatology And Venereology Congress
Benzinga · 09/21 13:23
More
About QTTB
Q32 Bio Inc. is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing therapies for alopecia areata and other autoimmune and inflammatory diseases. The Company is advancing bempikibart (ADX-914), a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Additional discovery and earlier development efforts from its complement inhibitor platform include ADX-096, a C3d mAb – CR1 fusion protein with preclinical data supportive of its use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition.

Webull offers Q32 Bio Inc stock information, including NASDAQ: QTTB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QTTB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QTTB stock methods without spending real money on the virtual paper trading platform.